For decades, one of the first instructions many people received after an atrial fibrillation diagnosis was to give up coffee. A new commentary published in Cardiovascular Research argues that instruction deserves reconsideration, and it points to randomized evidence rather than to observational patterns.
Christopher Wong and Gregory Marcus, the investigators behind the DECAF trial, reviewed the findings in an article published this week. Among patients with atrial fibrillation or atrial flutter undergoing cardioversion, those assigned to drink at least one cup of caffeinated coffee daily had a 39 percent lower hazard of clinically detected recurrence over six months than those assigned to avoid coffee and caffeine, with no difference in adverse events.
The reason this matters more than the usual coffee headline is the study design. This was a randomized trial in people who already had the condition, not a population survey of healthy adults.
The Trial That Tested the Restriction Directly
DECAF, an acronym for Does Eliminating Coffee Avoid Fibrillation, enrolled 200 adults in Australia, Canada and the United States who were regular coffee drinkers and had persistent atrial fibrillation or atrial flutter with a history of the arrhythmia. All were scheduled for electrical cardioversion, the procedure that uses a controlled shock to restore normal rhythm.
Participants were randomly assigned either to drink at least one cup of caffeinated coffee or an espresso shot daily, or to abstain from coffee and caffeine entirely, and were then followed for six months. The trial that tested the restriction was conducted by researchers at the University of California, San Francisco, and the University of Adelaide with National Institutes of Health support, presented at the American Heart Association's annual meeting, and published in JAMA.
In absolute terms, recurrence occurred in 47% of the coffee group and 64% of the abstinence group, according to the reported trial results. The hazard ratio was 0.61, with a 95% confidence interval of 0.42 to 0.89.
Marcus, a cardiologist and professor of medicine at UCSF, has described the clinical reality that motivated the trial. "It is very common for me to encounter patients who have stopped drinking caffeinated coffee only because their physician has told them to do so," he told NBC News, referring to advice given because of their atrial fibrillation.
The Limitations That Keep This from Being a Recommendation
The commentary itself stops short of claiming coffee protects the heart, and readers should stop there too.
The trial was open-label, meaning participants knew their assignment. In a study where the outcome includes clinically detected recurrence, awareness can influence behavior and symptom reporting. The sample of 200 was modest for a cardiovascular outcome trial, and adherence was imperfect: about a third of the abstinence group admitted drinking at least one cup during the study.
The cohort was also narrow. Average age was around 70, roughly 71 percent were men and 80 percent identified as white, all were regular coffee drinkers, and by design nobody who believed coffee triggered their own arrhythmia was likely to enroll in a trial that might require them to drink it. That last point matters most because it means the study may underrepresent the very group most likely to be harmed.
There is also a plausible indirect mechanism. Marcus has suggested that coffee increases physical activity, which is independently associated with lower atrial fibrillation risk. If that is the pathway, coffee is a marker rather than a treatment.
The authors conclude that modest caffeinated coffee consumption is unlikely to precipitate or worsen atrial fibrillation in most patients, and that further research is needed to determine whether it confers genuine benefit. That is a narrower claim than the surrounding headlines.
Where This Sits Against Broader Coffee Guidance
MedicalDaily reported this summer that the American Heart Association's scientific statement concluded up to five cups of coffee daily is safe for most adults, citing large cohort studies associating moderate-to-high consumption with lower rates of heart failure, coronary heart disease, stroke and atrial fibrillation.
That statement addressed the general adult population and rested largely on observational data. The relevant distinction is whether coffee causes atrial fibrillation in healthy people or worsens it in people who already have it. DECAF addresses the second question, the one patients actually ask after a diagnosis.
The AHA statement also noted that certain patients with arrhythmias should discuss their coffee intake with a clinician, and that this guidance has not been superseded.
Energy drinks are a separate matter entirely. High-dose caffeine products contain quantities and combinations that these findings do not cover, and extrapolating from coffee to those products is not supported.
Practical Guidance for People Living with AFib
Nobody should change caffeine intake based on a news article, and anyone who stopped drinking coffee on a physician's advice should raise it with that physician rather than simply resuming.
The useful conversation is specific. Reasonable questions include whether the coffee restriction was based on general practice or on something in the individual's own history, whether symptom diaries showed a pattern linking caffeine to episodes, and whether resuming modest consumption is reasonable given other conditions and medications.
Individual triggers remain real even when population-level evidence does not support blanket restriction. Someone who has repeatedly observed that caffeine precedes their episodes has information about themselves that a trial average does not override.
Caffeine also interacts with sleep, and sleep disruption is itself associated with atrial fibrillation episodes. Timing may matter as much as quantity.
None of this changes the treatments that reduce stroke risk. Anticoagulation decisions, rate and rhythm control, management of blood pressure, sleep apnea, alcohol use, and weight remain the substance of atrial fibrillation care. Anyone experiencing a new or prolonged episode with chest pain, shortness of breath, fainting or signs of stroke should seek emergency evaluation.
Larger randomized trials would be required before guidelines change. MedicalDaily will report on subsequent trials and on any revision to professional society guidance on caffeine in atrial fibrillation.
Key Questions Answered
What did the DECAF trial find? Among 200 adults with atrial fibrillation or flutter undergoing cardioversion, those assigned to drink at least one cup of caffeinated coffee daily had a 39 percent lower hazard of clinically detected recurrence over six months, with recurrence in 47 percent versus 64 percent.
Does this prove coffee protects the heart? No. The commentary authors say that modest coffee intake is unlikely to precipitate or worsen atrial fibrillation in most patients, and that more research is needed to determine whether there is any genuine benefit.
What are the main limitations? The trial was open-label, the sample was modest at 200 participants, adherence in the abstinence group was imperfect, and the cohort was skewed older, male, and white.
Could something other than caffeine explain the result? Possibly. One proposed pathway is that coffee increases physical activity, which is independently associated with lower atrial fibrillation risk.
Does this apply to energy drinks? No. High-dose caffeine products differ in quantity and composition, and these findings do not extend to them.
Should someone with AFib resume coffee? Not based on a news report. Anyone told to stop should discuss with their clinician whether the restriction was based on general practice or on their own documented pattern.
Does this change AFib treatment? No. Anticoagulation, rate and rhythm control, and management of blood pressure, sleep apnea, alcohol use, and weight remain the substance of care.
